Michigan Institute of Urology Opens Dedicated Outpatient Medical Center for Minimally Invasive Health Care
The Michigan Institute of Urology is partnering with Prostate Centers USA and opening IR Centers at MIU, a dedicated outpatient medical center for interventional radiology procedures in Troy.
The new center, opening Dec. 27, will provide patients with the option of minimally invasive treatments, which many individuals prefer due to their less invasive nature.
Leading IR Centers at MIU will be Dr. Scott Schwartz, a vascular interventional radiologist who previously served as the division chief of interventional radiology at Henry Ford Hospital. Schwartz specializes in interventional and embolization techniques.
“We are thrilled to have Dr. Schwartz leading our efforts to provide more minimally invasive therapies to our patients,” says Dr. Mitchell Hollander, CEO of MIU. “His extensive experience and pioneering work in the field make him an exceptional addition to our team.”
The center will offer a comprehensive range of treatments, including prostate artery embolization for men suffering from benign prostatic hyperplasia with very large prostates. Benign prostatic hyperplasia, also known as an enlarged prostate, can cause symptoms such as increased urinary frequency, weak urine stream, and difficulty urinating.
During a prostate artery embolization procedure, the interventional radiologist guides a microcatheter into the blood vessels supplying the prostate. Microscopic beads are then injected into these blood vessels, temporarily blocking the blood flow to the prostate gland. This causes the prostate to shrink, soften, and eventually be absorbed over time, providing relief and improvement of symptoms within two to three weeks. Importantly, this procedure does not require surgical incision or the insertion of a device into the urethra.
In addition to prostate artery embolization, IR Centers at MIU will expand their services to include other minimally invasive procedures targeting conditions such as varicoceles for male infertility, uterine fibroids, pelvic congestion syndrome, and hemorrhoids.
